JAGX
Price
$2.10
Change
-$0.12 (-5.41%)
Updated
Aug 7, 04:59 PM (EDT)
Capitalization
4.02M
MRNA
Price
$26.62
Change
-$0.09 (-0.34%)
Updated
Aug 7, 04:59 PM (EDT)
Capitalization
10.35B
83 days until earnings call
Interact to see
Advertisement

JAGX vs MRNA

Header iconJAGX vs MRNA Comparison
Open Charts JAGX vs MRNABanner chart's image
Jaguar Health
Price$2.10
Change-$0.12 (-5.41%)
Volume$381
Capitalization4.02M
Moderna
Price$26.62
Change-$0.09 (-0.34%)
Volume$111.61K
Capitalization10.35B
JAGX vs MRNA Comparison Chart in %
Loading...
JAGX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MRNA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
JAGX vs. MRNA commentary
Aug 08, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is JAGX is a Buy and MRNA is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 08, 2025
Stock price -- (JAGX: $2.10 vs. MRNA: $26.61)
Brand notoriety: JAGX: Not notable vs. MRNA: Notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: JAGX: 44% vs. MRNA: 85%
Market capitalization -- JAGX: $4.02M vs. MRNA: $10.35B
JAGX [@Biotechnology] is valued at $4.02M. MRNA’s [@Biotechnology] market capitalization is $10.35B. The market cap for tickers in the [@Biotechnology] industry ranges from $199.59B to $0. The average market capitalization across the [@Biotechnology] industry is $2.34B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

JAGX’s FA Score shows that 1 FA rating(s) are green whileMRNA’s FA Score has 1 green FA rating(s).

  • JAGX’s FA Score: 1 green, 4 red.
  • MRNA’s FA Score: 1 green, 4 red.
According to our system of comparison, MRNA is a better buy in the long-term than JAGX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

JAGX’s TA Score shows that 4 TA indicator(s) are bullish while MRNA’s TA Score has 5 bullish TA indicator(s).

  • JAGX’s TA Score: 4 bullish, 2 bearish.
  • MRNA’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, JAGX is a better buy in the short-term than MRNA.

Price Growth

JAGX (@Biotechnology) experienced а +2.94% price change this week, while MRNA (@Biotechnology) price change was -9.98% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.18%. For the same industry, the average monthly price growth was +8.39%, and the average quarterly price growth was +12.02%.

Reported Earning Dates

MRNA is expected to report earnings on Oct 30, 2025.

Industries' Descriptions

@Biotechnology (+1.18% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
MRNA($10.4B) has a higher market cap than JAGX($4.02M). MRNA YTD gains are higher at: -36.003 vs. JAGX (-91.683). JAGX has higher annual earnings (EBITDA): -37.39M vs. MRNA (-2.72B). MRNA has more cash in the bank: 5.13B vs. JAGX (5.69M). JAGX has less debt than MRNA: JAGX (38.3M) vs MRNA (741M). MRNA has higher revenues than JAGX: MRNA (3.06B) vs JAGX (11.6M).
JAGXMRNAJAGX / MRNA
Capitalization4.02M10.4B0%
EBITDA-37.39M-2.72B1%
Gain YTD-91.683-36.003255%
P/E Ratio0.01N/A-
Revenue11.6M3.06B0%
Total Cash5.69M5.13B0%
Total Debt38.3M741M5%
FUNDAMENTALS RATINGS
JAGX vs MRNA: Fundamental Ratings
JAGX
MRNA
OUTLOOK RATING
1..100
6363
VALUATION
overvalued / fair valued / undervalued
1..100
30
Undervalued
59
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10096
PRICE GROWTH RATING
1..100
9764
P/E GROWTH RATING
1..100
1003
SEASONALITY SCORE
1..100
290

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

JAGX's Valuation (30) in the Pharmaceuticals Generic industry is in the same range as MRNA (59) in the Biotechnology industry. This means that JAGX’s stock grew similarly to MRNA’s over the last 12 months.

JAGX's Profit vs Risk Rating (100) in the Pharmaceuticals Generic industry is in the same range as MRNA (100) in the Biotechnology industry. This means that JAGX’s stock grew similarly to MRNA’s over the last 12 months.

MRNA's SMR Rating (96) in the Biotechnology industry is in the same range as JAGX (100) in the Pharmaceuticals Generic industry. This means that MRNA’s stock grew similarly to JAGX’s over the last 12 months.

MRNA's Price Growth Rating (64) in the Biotechnology industry is somewhat better than the same rating for JAGX (97) in the Pharmaceuticals Generic industry. This means that MRNA’s stock grew somewhat faster than JAGX’s over the last 12 months.

MRNA's P/E Growth Rating (3) in the Biotechnology industry is significantly better than the same rating for JAGX (100) in the Pharmaceuticals Generic industry. This means that MRNA’s stock grew significantly faster than JAGX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
JAGXMRNA
RSI
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
74%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 2 days ago
76%
Momentum
ODDS (%)
N/A
Bearish Trend 2 days ago
85%
MACD
ODDS (%)
N/A
Bearish Trend 2 days ago
73%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
79%
Bearish Trend 2 days ago
85%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
84%
Advances
ODDS (%)
Bullish Trend 3 days ago
81%
Bullish Trend 16 days ago
77%
Declines
ODDS (%)
Bearish Trend 7 days ago
90%
Bearish Trend 2 days ago
85%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
86%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
77%
View a ticker or compare two or three
Interact to see
Advertisement
JAGX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MRNA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
REVB2.550.05
+2.00%
Revelation Biosciences Inc
DINO43.550.19
+0.44%
HF Sinclair Corp
DEI14.52-0.16
-1.09%
Douglas Emmett
GTN4.14-0.28
-6.33%
Gray Media Inc
ENTX1.80-0.18
-9.09%
Entera Bio Ltd